Indian billionaire Adani to invest $686.2m to build 2 health campuses
Billionaire Gautam Adani’s family plans to invest 60 billion rupees ($686.18 million) to set up two health campuses in the Indian cities of.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
Billionaire Gautam Adani’s family plans to invest 60 billion rupees ($686.18 million) to set up two health campuses in the Indian cities of.
Bain Capital, a US-based private investment company, will buy the pharmaceutical arm of the Mitsubishi Chemical Group Corp. for $3.3 billion, according to.
Tedros Adhanom Ghebreyesus, the Director-General of the World Health Organization, has given a four-point rebuttal to the US government’s accusations against the global.
Franco-Italian EssilorLuxottica SA got approval from the Food and Drug Administration to market its over-the-counter audio glasses in the US for people with.
AstraZeneca’s drug for treating limited-stage small cell lung cancer got a recommendation for approval from an EU regulator panel, according to the British-Swedish.
Merck & Co. halted its final-phase study of its experimental drug for pulmonary arterial hypertension after previous studies proved its “robust efficacy,” according.
The UNAIDS has welcomed a move by the United States Secretary of State, Marco Rubio, to approve an “Emergency Humanitarian Waiver” to allow.
A US government’s decision to pause funding for HIV programmes in low and middle-income countries will take the world back to the 1980s.
Anglo-Swedish AstraZeneca Plc., and Japan’s Daiichi Sankyo’s therapy to treat a certain form of breast cancer has been approved by the US drug.
Biogen Inc. and its Japanese partner, Eisai Co. Ltd., announced that the US regulator had approved four-weekly maintenance dosing for its Alzheimer's drug.